Ján Király, M.A., PhD

Last update: 23. 10. 2023

I. BASIC INFORMATION
I.1 Surname Király
I.2 Name Ján
I.3 Titles M.A., PhD
I.4 Year of birth 1982
I.5 Name of the workplace University of Veterinary Medicine and Pharmacy in Košice, Department of Microbiology and Immunology
I.6 Address of the workplace Komenského 73, 041 81 Košice, Slovak Republic
I.7 Position researcher
I.8 E-mail address jan.kiraly@uvlf.sk
I.9 Hyperlink to the entry of a person in the Register of university staff https://www.portalvs.sk/regzam/detail/19925
I.10 Name of the study field in which a person works at the university biology
I.11 ORCID iD 3
3 Optional item.

II. HIGHER EDUCATION AND FURTHER QUALIFICATION GROWTH
II.a Name of the university or institution II.b Year II.c Study field and programme
II.1 First degree of higher education Pavol Jozef Šafárik University in Košice, Faculty of Science 2004 biology
II.2 Second degree of higher education Pavol Jozef Šafárik University in Košice, Faculty of Medicine 2006 biology, genetics and molecular cytology
II.3 Third degree of higher education Faculty of Natural Sciences, Comenius University 2012 virology
II.4 Associate professor
II.5 Professor
II.6 Doctor of Science (DrSc.)

III. CURRENT AND PREVIOUS EMPLOYMENT
III.a Occupation-position III.b Institution III.c Duration
scientist University of Veterinary Medicine and Pharmacy in Košice 2013 up to now

IV. DEVELOPMENT OF PEDAGOGICAL, PROFESSIONAL, LANGUAGE, DIGITAL AND OTHER SKILLS
IV.a Activity description, course name, other IV.b Name of the institution IV.c Year

V. OVERVIEW OF ACTIVITIES WITHIN THE TEACHING CAREER AT THE UNIVERSITY
V.1. Overview of the profile courses taught in the current academic year according to study programmes
V.1.a Name of the profile course V.1.b Study programme V.1.c Degree V.1.d Field of study

V.2. Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year 4
V.2.a Study programme V.2.b Degree V.2.d Field of study
4 According to Art. 6 para. 4 of the Standards for the Study Programme.

V.3. Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.3.a Name of the field of habilitation procedure and inaugural procedure V.3.b Study field to which it is assigned

V.4. Overview of supervised final theses
V.4.a Bachelor's (first degree) V.4.b Diploma (second degree) V.4.c Dissertation (third degree)
V.4.1 Number of currently supervised theses 0 1 0
V.4.2 Number of defended theses 0 3 0

V.5. Overview of other courses taught in the current academic year according to study programmes
V.5.a Name of the course V.5.b Study programme V.5.c Degree V.5.d Field of study
Introduction to genetic engineeringfeed and foodstuff safety full time slovak languagefirstveterinary medicine
Introduction to genetic engineeringfeed and foodstuff safety external slovak languagefirstveterinary medicine
Microbiologypharmacy (join study programme) full time slovak languagecombined 1st and 2ndpharmacy
Introduction to genetic engineeringfood hygiene full time slovak languagecombined 1st and 2ndveterinary medicine
Immunologygeneral veterinary medicine full time slovak languagecombined 1st and 2ndveterinary medicine
Introduction to genetic engineeringgeneral veterinary medicine full time slovak languagecombined 1st and 2ndveterinary medicine
Laboratory diagnosisgeneral veterinary medicine full time slovak languagecombined 1st and 2ndveterinary medicine

VI. OVERVIEW OF THE RESEARCH/ARTISTIC/OTHER OUTPUTS
VI.1. Overview of the research/artistic/other outputs and the corresponding citations
VI.1.a Overall VI.1.b Over the last six years
VI.1.1 Number of the research/artictic/other outputs 58 34
VI.1.2 Number of the research/artictic/other outputs registered in the Web of Science or Scopus databases 7 4
VI.1.3 Number of citations corresponding to the research/artictic/other outputs 48 29
VI.1.4 Number of citations registered in the Web of Science or Scopus databases 42 25
VI.1.5 Number of invited lectures at the international, national level 1 1

VI.2. The most significant research/artistic/other outputs 5
1. STANEKOVÁ, Zuzana - KIRÁLY, Ján - STROPKOVSKÁ, Andrea - MIKUŠKOVÁ, Tatiana - MUCHA, Vojtech - KOSTOLANSKÝ, František - VAREČKOVÁ, Eva. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. In: Acta Virologica. 2011. ISSN 0001-723X, Vol. 55, č. 1(2011), s. 61-67.
(2011: 0.682 - IF, 32 - H-index, 0.764 - IF 5y, 0.348 - SJR, Q3 - SJR Best Q, Q4 - JCR Best Q)
2. ENGLEROVÁ, Karolína - BEDLOVIČOVÁ, Zdenka - NEMCOVÁ, Radomíra - KIRÁLY, Ján - MAĎAR, Marián - HAJDUČKOVÁ, Vanda - STYKOVÁ, Eva - MUCHA, Rastislav - REIFFOVÁ, Katarína. Bacillus amyloliquefaciens-derived lipopeptide biosurfactants inhibit biofilm formation and expression of biofilm-related genes of Staphylococcus aureus. In: Antibiotics. 2021. ISSN 2079-6382, Vol. 10, no. 10 (2021), art. no. 1252, p. [1-18]
(2021: 5.222 - IF, 47 - H-index, 5.396 - IF 5y, 0.785 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)
5 Maximum of five most significant outputs, if the RATP form is attached to the application.

VI.3. The most significant research/artistic/other outputs over the last six years 6
1. ENGLEROVÁ, Karolína - BEDLOVIČOVÁ, Zdenka - NEMCOVÁ, Radomíra - KIRÁLY, Ján - MAĎAR, Marián - HAJDUČKOVÁ, Vanda - STYKOVÁ, Eva - MUCHA, Rastislav - REIFFOVÁ, Katarína. Bacillus amyloliquefaciens-derived lipopeptide biosurfactants inhibit biofilm formation and expression of biofilm-related genes of Staphylococcus aureus. In: Antibiotics. 2021. ISSN 2079-6382, Vol. 10, no. 10 (2021), art. no. 1252, p. [1-18]
(2021: 5.222 - IF, 47 - H-index, 5.396 - IF 5y, 0.785 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)
6 Maximum of five most significant outputs over the last six years, if the RATP form is attached to the application.

VI.4. The most significant citations corresponding to the research/artistic/other outputs 7
1. STANEKOVÁ, Zuzana - KIRÁLY, Ján - STROPKOVSKÁ, Andrea - MIKUŠKOVÁ, Tatiana - MUCHA, Vojtech - KOSTOLANSKÝ, František - VAREČKOVÁ, Eva. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. In: Acta Virologica. 2011. ISSN 0001-723X, Vol. 55, č. 1(2011), s. 61-67.
(2011: 0.682 - IF, 32 - H-index, 0.764 - IF 5y, 0.348 - SJR, Q3 - SJR Best Q, Q4 - JCR Best Q)
[1] KRAMMER, Florian - PALESE, Peter. Advances in the development of influenza virus vaccines. In NATURE REVIEWS DRUG DISCOVERY. ISSN 1474-1776, 2015, vol. 14, no. 3, pp. 167.
7 Maximum of five most significant citations, if the RATP form is attached to the application.

VI.5. Participation in conducting (leading) the most important research projects or art projects over the last six years 8
1. APVV APVV-15-0377 "Synergistic effect of secondary metabolites of plants and products of probiotic bacteria on inhibition of biofilm-producing pathogens.", Duration: 2016 - 2020
8 Maximum of five most significant projects, if the RATP form is attached to the application. In addition to the name and brief characteristics of the project, the type of participation is indicated (in Slovak and in English), if possible, a hyperlink to the project and its outputs and citations are stated as well.

VII. OVERVIEW OF ORGANIZATIONAL EXPERIENCE RELATED TO HIGHER EDUCATION AND RESEARCH/ARTISTIC/OTHER ACTIVITIES 9
VII.a Activity, position VII.b Name of the institution, board VII.c Duration
9 E.g. academic positions, memberships in editorial boards and in scientific and professional societies.

VIII. OVERVIEW OF INTERNATIONAL MOBILITIES AND VISITS ORIENTED ON EDUCATION AND RESEARCH/ARTISTIC/ OTHER ACTIVITIES IN THE GIVEN FIELD OF STUDY
VIII.a Name of the institution VIII.b Address of the institution VIII.c Duration (indicate the duration of stay) VIII.d Mobility scheme, employment contract, other (describe)

IX. OTHER RELEVANT FACTS 10
IX.a If relevant, other activities related to higher education or research/artictic/other activities are mentioned
10 Maximum of 1800 characters, if the RATP form is attached to the application.
Skip to content